Regulators have opened a one-time gene therapy to some of the youngest patients with sickle cell disease. On July 1, 2026, the U.S. Food and Drug Administration approved Casgevy for patients as young as 2 years old who have sickle cell disease with recurrent pain crises or transfusion-dependent beta thalassemia. It is the first gene therapy cleared for children in that age group with sickle cell disease, extending a treatment that had previously been limited to patients 12 and older.
What the therapy does
Casgevy, known generically as exagamglogene autotemcel, is a gene therapy made from a patient’s own blood stem cells. Those cells are edited outside the body using CRISPR/Cas9 genome-editing technology and then infused back and engrafted in the bone marrow, administered as a one-time single dose. The editing is designed to boost production of fetal hemoglobin, a form of the oxygen-carrying protein that helps keep red blood cells from forming the abnormal sickle shapes that drive the disease.
Sickle cell disease affects the red blood cells that carry hemoglobin throughout the body, and it can cause episodes of severe pain known as sickle cell crises, or vaso-occlusive crises. By addressing the underlying cause, the therapy is intended to eliminate those crises. In transfusion-dependent beta thalassemia, a separate genetic blood disorder marked by abnormally low hemoglobin, the treatment raises fetal and total hemoglobin levels with the goal of ending the need for regular blood transfusions.
The procedure is demanding. Before receiving Casgevy, patients undergo full myeloablative conditioning, a high-intensity preparatory treatment given ahead of a stem cell transplant or gene therapy. That step underscores that this is a complex, intensive intervention rather than a simple prescription, which matters when weighing it for very young children.
The evidence behind the expansion
The FDA based the approval on trials in children aged 5 to under 12, then extrapolated the findings to reach down to age 2. In the sickle cell trial, which included 11 patients, all eight who were evaluable for efficacy achieved the primary outcome — no protocol-defined severe pain crises for at least 12 consecutive months within the first 24 months after infusion. In the thalassemia trial of 15 patients, eight of the nine evaluable patients reached transfusion independence for 12 consecutive months, with a median duration of 20.1 months.
Based on those results and the product’s characteristics, the agency granted an extrapolation to the younger pediatric population, expanding the indication down to age 2 for both conditions. The rationale, described by FDA officials, rests on evidence that earlier treatment reduces the risk of lasting organ damage, opening what one reviewer called “a critical window for intervention” for children whose disease can affect growth and long-term health.
The safety profile carries real risks. The most common adverse reactions were mucositis, an inflammation of mucous membranes, and febrile neutropenia, a fever linked to low levels of a type of white blood cell, along with decreased appetite in sickle cell patients. The prescribing information also warns of neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity reactions and the possibility of off-target genome editing, in which the CRISPR process makes unintended changes elsewhere in the genome.
What it means for families and what to watch
For families of young children with severe sickle cell disease, the approval adds a treatment option that targets the root of the disease rather than only managing symptoms. The trial data point to a meaningful chance of eliminating the painful crises that define the condition, and for thalassemia patients, a path off regular transfusions. Because the therapy is a one-time treatment, the appeal is durability — the hope of a lasting effect from a single course rather than lifelong management.
Important questions remain unanswered by the trials themselves. The efficacy findings come from small groups of patients, and the extension to children as young as 2 relies on extrapolation rather than direct testing in that age range, so real-world results in the youngest patients will accumulate over time. The intensive conditioning regimen, the serious potential adverse effects and the long-term uncertainty around off-target editing all mean this is a decision families will need to make carefully with their care teams. The FDA granted the approval to Vertex Pharmaceuticals, and the review moved quickly — just 53 days after filing — as the eighth approval selected for the agency’s Commissioner’s National Priority Voucher pilot program.
What to watch next is how the therapy performs outside the tightly controlled trial setting, particularly in the youngest patients, and how access questions such as availability and cost play out, which the FDA announcement does not address. For now, the approval marks a notable widening of who can receive a CRISPR-based treatment for these blood disorders.
More from Morning Overview
- The NSA issues an urgent warning to all phone users about a setting most people leave on
- 5,000-year-old wolves on remote island upend domestication theory
- Scientists may have found a Type II civilization
- EPA finally kills ‘stupid feature’ in 60% of U.S. cars after 14 years of driver rage
*This article was researched with the help of AI, with human editors creating the final content.
